Detalhe da pesquisa
1.
Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.
Cancer
; 122(13): 2050-6, 2016 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27191689
2.
Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis.
Blood
; 112(7): 2709-12, 2008 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18594024
3.
Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.
Clin Lymphoma Myeloma
; 8(6): 352-5, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19064400
4.
Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates.
Med Oral Patol Oral Cir Bucal
; 12(4): E336-40, 2007 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17664922
5.
Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome.
Clin Lymphoma Myeloma Leuk
; 11(1): 44-9, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21454189
6.
Medium-term results of percutaneous vertebroplasty in multiple myeloma.
Eur J Haematol
; 77(1): 7-13, 2006 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16608504